RU97108766A -
METHOD FOR TREATING TOXIC-SEPTIC CONDITIONS IN NEWBORN CHILDREN
- Google Patents
METHOD FOR TREATING TOXIC-SEPTIC CONDITIONS IN NEWBORN CHILDREN
Info
Publication number
RU97108766A
RU97108766ARU97108766/14ARU97108766ARU97108766ARU 97108766 ARU97108766 ARU 97108766ARU 97108766/14 ARU97108766/14 ARU 97108766/14ARU 97108766 ARU97108766 ARU 97108766ARU 97108766 ARU97108766 ARU 97108766A
Российская медицинская академия последипломного образования Министерства здравоохранения РФ
Filing date
Publication date
Application filed by Российская медицинская академия последипломного образования Министерства здравоохранения РФfiledCriticalРоссийская медицинская академия последипломного образования Министерства здравоохранения РФ
Priority to RU97108766ApriorityCriticalpatent/RU2144837C1/en
Priority claimed from RU97108766Aexternal-prioritypatent/RU2144837C1/en
Publication of RU97108766ApublicationCriticalpatent/RU97108766A/en
Application grantedgrantedCritical
Publication of RU2144837C1publicationCriticalpatent/RU2144837C1/en
Способ лечения токсико-септических состояний у новорожденных детей, включающий введение антибактериальных препаратов и 5% раствора глюкозы, отличающийся тем, что раствор глюкозы предварительно облучают рентгеновским излучением в дозе 0,2 - 0,5 Гр/мл, а его введение осуществляют непосредственно до или после или одновременно с введением антибактериальных препаратов.A method of treating toxic-septic conditions in newborns, including the introduction of antibacterial drugs and a 5% glucose solution, characterized in that the glucose solution is pre-irradiated with X-ray at a dose of 0.2 - 0.5 Gy / ml, and its administration is carried out immediately before or after or simultaneously with the introduction of antibacterial drugs.
RU97108766A1997-06-041997-06-04Method for treating toxic septic states in newborn children
RU2144837C1
(en)
3-hydroxy-2-(4-methoxyphenyl)-5-(2-methylaminoethyl)-2-3,dihydro-5h-1,5-benzothiazepin-4-one derivatives,their preparation and their application in therapy
(-) - 2-PYRAZOLINE COMPOUND, THEIR OPTICAL UNLOCKING AND THERAPEUTIC AGENT FOR THE TREATMENT OF CEREBRAL VEGETABLE DISEASES, CONTAINING THIS COMPOUND AS AN ACTIVE INGREDIENT.
Treatment of advanced soft tissue sarcomas with low-dose methotrexate: a phase II trial by the European Organization of Research on Treatment for Cancer (EORTC) Soft Tissue and Bone Sarcoma Group